Dataset Information

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

ABSTRACT: Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies characterized by dysplasia, ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia. Sequencing of MDS genomes has identified mutations in genes implicated in RNA splicing, DNA modification, chromatin regulation, and cell signaling. We sequenced 111 genes across 738 patients with MDS or closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neoplasms) to explore the role of acquired mutations in MDS biology and clinical phenotype. Seventy-eight percent of patients had 1 or more oncogenic mutations. We identify complex patterns of pairwise association between genes, indicative of epistatic interactions involving components of the spliceosome machinery and epigenetic modifiers. Coupled with inferences on subclonal mutations, these data suggest a hypothesis of genetic "predestination," in which early driver mutations, typically affecting genes involved in RNA splicing, dictate future trajectories of disease evolution with distinct clinical phenotypes. Driver mutations had equivalent prognostic significance, whether clonal or subclonal, and leukemia-free survival deteriorated steadily as numbers of driver mutations increased. Thus, analysis of oncogenic mutations in large, well-characterized cohorts of patients illustrates the interconnections between the cancer genome and disease biology, with considerable potential for clinical application.

SUBMITTER: Papaemmanuil E

PROVIDER: S-EPMC3837510 | biostudies-other | 2013 Nov

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil Elli E Gerstung Moritz M Malcovati Luca L Tauro Sudhir S Gundem Gunes G Van Loo Peter P Yoon Chris J CJ Ellis Peter P Wedge David C DC Pellagatti Andrea A Shlien Adam A Groves Michael John MJ Forbes Simon A SA Raine Keiran K Hinton Jon J Mudie Laura J LJ McLaren Stuart S Hardy Claire C Latimer Calli C Della Porta Matteo G MG O'Meara Sarah S Ambaglio Ilaria I Galli Anna A Butler Adam P AP Walldin Gunilla G Teague Jon W JW Quek Lynn L Sternberg Alex A Gambacorti-Passerini Carlo C Cross Nicholas C P NC Green Anthony R AR Boultwood Jacqueline J Vyas Paresh P Hellstrom-Lindberg Eva E Bowen David D Cazzola Mario M Stratton Michael R MR Campbell Peter J PJ

Blood 20130912 22

Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies characterized by dysplasia, ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia. Sequencing of MDS genomes has identified mutations in genes implicated in RNA splicing, DNA modification, chromatin regulation, and cell signaling. We sequenced 111 genes across 738 patients with MDS or closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myelopro ...[more]

PMID: 24030381

Similar Datasets

Project description:BackgroundMyelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia. Somatic mutations may influence the clinical phenotype but are not included in current prognostic scoring systems.MethodsWe used a combination of genomic approaches, including next-generation sequencing and mass spectrometry-based genotyping, to identify mutations in samples of bone marrow aspirate from 439 patients with myelodysplastic syndromes. We then examined whether the mutation status for each gene was associated with clinical variables, including specific cytopenias, the proportion of blasts, and overall survival.ResultsWe identified somatic mutations in 18 genes, including two, ETV6 and GNAS, that have not been reported to be mutated in patients with myelodysplastic syndromes. A total of 51% of all patients had at least one point mutation, including 52% of the patients with normal cytogenetics. Mutations in RUNX1, TP53, and NRAS were most strongly associated with severe thrombocytopenia (P<0.001 for all comparisons) and an increased proportion of bone marrow blasts (P<0.006 for all comparisons). In a multivariable Cox regression model, the presence of mutations in five genes retained independent prognostic significance: TP53 (hazard ratio for death from any cause, 2.48; 95% confidence interval [CI], 1.60 to 3.84), EZH2 (hazard ratio, 2.13; 95% CI, 1.36 to 3.33), ETV6 (hazard ratio, 2.04; 95% CI, 1.08 to 3.86), RUNX1 (hazard ratio, 1.47; 95% CI, 1.01 to 2.15), and ASXL1 (hazard ratio, 1.38; 95% CI, 1.00 to 1.89).ConclusionsSomatic point mutations are common in myelodysplastic syndromes and are associated with specific clinical features. Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor overall survival in patients with myelodysplastic syndromes, independently of established risk factors. (Funded by the National Institutes of Health and others.).

Dataset Information

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Publications

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets